Physician profile
Roosevelt Gloyd
NPI 1184646796
$4,302.96
in general payments reported to CMS, 2019-2025
17 companies · $763 in 2025
The $763 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $120 · 2021: $355 · 2022: $1,183 · 2023: $745 · 2024: $572 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,080.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $938.59 | 2019-2025 | Precision7, Rocklatan, Clareon |
| Abbvie INC. | $788.48 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $578.27 | 2019-2021 | |
| Coopervision INC. | $537.11 | 2022-2024 | Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $463.31 | 2022-2023 | Infuse, Revive, Vyzulta |
| Oyster Point Pharma, INC. | $278.11 | 2022-2024 | Tyrvaya, Ryzumvi |
| Shire North American Group INC | $149.58 | 2019 | |
| Ocular Therapeutix, INC. | $125.00 | 2024 | Dextenza |
| Sun Pharmaceutical Industries INC. | $120.75 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $104.00 | 2024-2025 | Xdemvy |
| Astellas Pharma US INC | $59.52 | 2025 | Izervay |
| Harrow Eye, LLC | $36.79 | 2025 | Vevye |
| Dompe US, INC. | $34.01 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $31.59 | 2022 | |
| Allergan, INC. | $20.97 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $18.98 | 2022 | |
| Thea Pharma INC. | $17.90 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roosevelt Gloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.